GlassScriptPhysician profile
Imad S Modawi
NPI 1124224415
$1,635.95
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3.84 · 2021: $159 · 2022: $422 · 2023: $879 · 2024: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $962 · Education: $89.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $961.94 |
| Education | $89.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $357.37 | 2021-2024 | Farxiga |
| Mallinckrodt Hospital Products INC. | $140.91 | 2021-2023 | Terlivaz |
| Gilead Sciences, INC. | $124.74 | 2023 | Veklury |
| Travere Therapeutics, INC. | $121.71 | 2022-2023 | |
| Opko Pharmaceuticals, LLC | $119.16 | 2022-2024 | Rayaldee |
| Vifor Pharma, INC. | $114.49 | 2022-2024 | Veltassa, Korsuva |
| Amgen INC. | $109.91 | 2021-2024 | Tavneos, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $93.92 | 2021-2023 | |
| Calliditas Therapeutics US INC. | $86.18 | 2022-2024 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $82.54 | 2021-2023 | Jynarque |
| Novo Nordisk INC | $73.32 | 2022-2024 | Rybelsus, Ozempic |
| Aurinia Pharma U.S., INC. | $60.15 | 2022-2023 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $45.93 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.81 | 2022-2023 | Jardiance |
| Ani Pharmaceuticals, INC. | $24.54 | 2023 | Purified Cortrophin Gel |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $23.27 | 2023 | |
| Ardelyx, INC. | $21.16 | 2023 | Ibsrela |
| Akebia Therapeutics INC | $3.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imad Modawi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.